Date of Award
Zeb Kramer, Ph.D.
Vincent Kling, Ph.D.
Previous research provides experimental evidence that cantharidin acts as an inhibitor of HSF1 in cancer cells whereas the similar norcantharidin exhibits no inhibitory activity on HSF1. This computational study utilized Autodock to suggest both binding site(s) and binding energies of cantharidin and norcantharidin on HSF1. This study found cantharidin to consistently bind stronger than norcantharidin in the same area on HSF1 when assuming a rigid protein structure.
Coyle, Daniel, "Ligand-Protein Binding of Cantharidin and Norcantharidin on HSF1: A Docking Study" (2019). HON499 projects. 23.